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Summary: 
iNKT cells were depleted in patients with advanced HIV infection, most significantly 
immunoregulatory CD4+ subsets.  
 
In patients with HIV-associated TB who developed TB-IRIS, iNKT cells were elevated 
with increased degranulation compared to non-IRIS patients, implicating iNKT cells in 
TB-IRIS immunopathology.    
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Abstract 
 
Rationale: Tuberculosis (TB) is the leading cause of mortality and morbidity in people living 
with HIV infection. HIV-infected patients with TB disease are at risk of the paradoxical TB-
associated immune reconstitution inflammatory syndrome (TB-IRIS) when they commence 
anti-retroviral therapy.  However, the pathophysiology is incompletely understood and 
specific therapy is lacking.  
 
Objectives: We investigated the hypothesis that invariant Natural Killer T (iNKT) cells 
contribute to innate immune dysfunction associated with TB-IRIS.  
 
Methods: In a cross-sectional study of 101 HIV-infected and -uninfected South African 
patients with active TB and controls, iNKT cells were enumerated using α-
galactosylceramide-loaded CD1d tetramers and subsequently functionally characterised by 
flow cytometry. In a second study of 49 HIV-1-infected TB patients commencing anti-
retroviral therapy, iNKT cells in TB-IRIS patients with non-IRIS controls were compared 
longitudinally.  
 
Measurements and main results: Circulating iNKT cells were reduced in HIV-1 infection, 
most significantly the CD4+ subset, which was inversely associated with HIV-1 viral load. 
iNKT cells in HIV-associated TB had increased surface CD107a expression, indicating 
cytotoxic degranulation. Relatively increased iNKT cell frequency in HIV-infected patients 
with active TB was associated with development of TB-IRIS following anti-retroviral therapy 
initiation. iNKT cells in TB-IRIS were CD4+CD8- subset deplete and degranulated around 
the time of TB-IRIS onset. 
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Conclusions: Reduced iNKT cell CD4+ subsets as a result of HIV-1 infection may skew 
iNKT cell functionality towards cytotoxicity. Increased CD4- cytotoxic iNKT cells may 
contribute to immunopathology in TB-IRIS. 
 
 
 
Key words: invariant Natural Killer T cell; HIV; tuberculosis; paradoxical immune 
reconstitution inflammatory syndrome (IRIS); innate.  
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Introduction 
Tuberculosis (TB) causes 1.6 million deaths annually and is the leading cause of death in 
HIV-1 infected people (1). Anti-retroviral therapy (ART) naive HIV-1-infected patients with 
TB are at risk of the paradoxical TB immune reconstitution inflammatory syndrome (TB-
IRIS) after commencing ART (2). Paradoxical TB-IRIS is characterised by an acute 
inflammatory response to Mycobacterium tuberculosis (Mtb) presenting as a clinical 
deterioration in a patient already receiving TB treatment, typically around two weeks post 
ART initiation (3). Paradoxical TB-IRIS is difficult to manage, frequently requiring non-
specific immunosuppression with corticosteroids. Risk factors include disseminated TB and 
low CD4 T cell count at ART initiation, but the pathophysiology is incompletely defined (4). 
Recent studies have identified potential contributory innate immune mechanisms, including 
neutrophil recruitment, inflammasome activation and proinflammatory cytokine excess (5-
10). These potential mechanisms have been recently reviewed (2) 
 
Invariant natural killer T (iNKT) cells are a T cell subset that bridge innate and adaptive 
immunity, therefore are of interest in TB-IRIS pathogenesis (11). Distinct from NK cells and 
conventional T cells, iNKT cells express an invariant T cell receptor comprised of Vα24 and 
Vβ11 in humans, and specifically recognise CD1d-presented lipid antigens, responding on 
activation with rapid cytokine production. Additionally, iNKT cells recognise and are 
potently activated by the marine sponge glycolipid α-galactosylceramide (α-galcer), bound to 
CD1d (12, 13).  
 
Mtb cell wall is lipid-rich and therefore CD1d-presented molecules that activate iNKT cells 
may have a role in host immunity to Mtb (14, 15). In vitro, iNKT cells directly restricted Mtb 
growth and were bactericidal (16). In mice, augmenting iNKT cell responses with α-galcer 
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improved BCG vaccine efficacy and anti-tuberculosis treatment responses (17, 18). In non-
human primates, increased iNKT cell frequency was associated with TB resistance (19). In 
humans, a limited number of studies have demonstrated numerical and functional defects of 
iNKT cells in active TB (20-23).  
 
We previously reported elevated expression of cytotoxic mediators, perforin and granzyme B, 
in peripheral blood mononuclear cells (PBMC) in response to Mtb antigen stimulation and 
elevated frequencies of cytotoxic cells expressing CD3 and V 24 T cell receptor in TB-IRIS 
patients compared to non-IRIS controls, suggesting that iNKT cells may play a role in TB-
IRIS (24). Here, we systematically investigated iNKT cells in cross-sectional and 
longitudinal studies addressing the hypothesis that iNKT cell dysfunction contributes to TB-
IRIS immunopathology. We describe for the first time iNKT cell aberration in HIV-
associated TB disease and increased cytotoxic iNKT cells in TB-IRIS patients.  
 
Methods 
Full methods are provided in the online supplement.  
Study Participants  
The study was approved by the University of Cape Town Human Research Ethics Committee 
(REF 516/2011). All participants provided written informed consent. Cross-sectional study 
participants were retrospectively designated into four categories:  
1) HIV-uninfected patients without active TB (HIV-TB-) 
2) HIV-uninfected patients with a new diagnosis of active TB (HIV-TB+)  
3) ART naïve, HIV-infected patients without active TB (HIV+TB-)  
4) ART naïve, HIV-infected patients with a new diagnosis of active TB (HIV+TB+).  
Longitudinal study participants were ART naïve HIV-1-infected patients with a CD4 count 
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<200 cells/ L and recently diagnosed TB. Longitudinal study visits occurred at TB diagnosis 
(TB0), ART initiation (ARV0), two (ARV2) and four (ARV4) weeks of ART and if new 
symptoms suggesting TB-IRIS occurred. TB-IRIS diagnosis was assigned retrospectively on 
expert case review, using consensus criteria (3).  
 
iNKT cell enumeration and characterisation 
PBMC were isolated over Ficoll and cryopreserved. Cells were rapidly thawed in warmed 
RPMI/10% FCS, before viability staining with Violet LIVE/DEAD
©
 Fixable stain kit 
(VIVID, Invitrogen, Paisley, UK), then washed and re-suspended for incubation with either 
α-galcer-loaded CD1d tetramer or control CD1d tetramer (Proimmune, Oxford, UK) for 30 
minutes on ice, protected from light. Subsequently, cells were washed, stained with antibody 
mastermix 1 (Supplementary Table S1) for 30 minutes at 4
o
C, washed and re-suspended in 
PBS, 1% Hi-FCS and 2% paraformaldehyde, then incubated for 1 hour, washed and 
resuspended for acquisition.  
 
Data acquisition and analysis 
Data were acquired on an LSRFortessa
TM
 (BD Biosciences, USA) and analysed using Flowjo 
software (Tree Star, Ashland, OR). iNKT cells were defined as CD3+ CD19- CD1d α-galcer 
tet+ Vβ11+ T cells. The gating strategy is shown in Figure 1A. iNKT cell frequency was 
calculated as a percentage of CD3+ CD19- live lymphocytes, with subtraction of the 
equivalent tetramer negative control proportion, and reported per million CD3+CD19- live 
lymphocytes. iNKT cell numbers were calculated by multiplying the iNKT cell frequency as 
a percentage of live lymphocytes with the total lymphocyte count per millilitre of peripheral 
blood (22).  
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Statistical analysis was performed using Prism 6 (GraphPad, UK) and STATA 
14. Unadjusted non-parametric analyses were by two-tailed Fisher’s Exact or Mann–Whitney 
U, or for comparisons of more than two groups, by Kruskal-Wallis with Dunn’s multiple 
comparisons test. In the cross-sectional study, we used a multivariable linear regression 
model to investigate differences in iNKT cell frequency and in percentage iNKT cell 
CD4/CD8 expression by disease category. In the longitudinal study, a multivariable negative 
binomial model was fitted to examine associations of iNKT cell frequency and number with 
TB-IRIS status, and a multivariate linear regression model to estimate difference in 
CD4/CD8 cell subset percentages between TB IRIS and non-IRIS patients. 
 
Results 
PBMC samples were available from 101 patients (see Table 1). HIV+TB+ patients compared 
to HIV+TB- patients had lower total CD4 counts but similar CD4 percentages, and higher 
HIV-1 viral loads. In HIV+TB+ compared to HIV-TB+, there were trends towards reduced 
cavitary (p=0.067), but increased miliary (p=0.051) and extra-pulmonary (p=0.054) TB 
presentation, indicating reduced destructive pulmonary pathology but more widely 
disseminated TB disease in HIV-infected patients (25).   
 
Circulating iNKT cells are depleted in HIV-1 infection and active TB 
In an unadjusted analysis, comparing iNKT cell frequency in HIV-1-infected and -uninfected 
patients, with and without active TB, we found that iNKT cell frequency was reduced in 
HIV+TB+ (p=0.001) and HIV+TB- (p=0.005) compared to HIV-TB- patients (Figure 1B and 
Table 2). Example plots are shown in Supplementary Figure S1. A similar pattern was 
observed in comparison of iNKT cell numbers (iNKT cells per ml, Figure 1C) and reduction 
in iNKT cells numbers was found in HIV-TB+ compared to HIV-TB- patients (p=0.044). 
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Linear regression comparing HIV-TB+, HIV+TB- and HIV+TB+ to HIV-TB- provided 
further evidence of association between reduced iNKT cell frequency in HIV+TB- (p=0.023) 
and HIV+TB+ (p=0.024) after adjustment for age and sex, but there was no evidence of a 
reduction in iNKT cell frequency in HIV-TB+ compared to HIV-TB- (p=0.301).  
 
CD4+ iNKT cell subsets are depleted in HIV-1 infection 
iNKT cells may exist as CD4+CD8-, CD4-CD8+, CD8+CD4+, or double negative (DN) 
subsets. CD4+ iNKT cells secrete both Th1 and Th2 cytokines and may be 
immunoregulatory, whilst CD8+ iNKT cells and DN iNKT cell subsets predominantly 
secrete Th1 cytokines and have increased cytotoxic functionality (26, 27). Unadjusted 
analyses showed that HIV-1 infection was associated with lower CD4+ iNKT cell 
percentages (Figure 2A) and frequency (CD4+ iNKT cells per million CD3+ CD19- live 
lymphocytes, Figure 2B) in patients with (p=0.007) and without (p=0.005) active TB. Active 
TB did not clearly reduce CD4+ iNKT cell percentage, but was associated with reduced 
CD4+ iNKT cell frequency in HIV-uninfected patients (Figure 2B, p=0.016). In HIV-
infected patients, total iNKT cell frequency did not correlate with peripheral blood CD4 T 
cell count, peripheral blood CD4 T cell percentage or HIV-1 viral load. However, CD4+ 
iNKT cell percentage was correlated with total peripheral blood CD4 T cell count (Figure 2C, 
r=0.456, p=0.001) and there was an inverse correlation with HIV-1 viral load (Figure 2D, r=-
0.571, p<0.001), indicating most severe depletion of CD4+ iNKT cells occurred in advanced 
HIV infection.  
 
Next, we examined CD4 and CD8 co-expression on iNKT cells. In HIV-TB-, we found 
CD4+CD8- (Figure 2E) and DN iNKT cells (Figure 2F) to be the predominant iNKT cell 
subsets constituting a median of 42.1% and 43.7%  of the iNKT cell population respectively. 
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However, compared to HIV-TB- patients, HIV-infected patients had reduced percentages of 
CD4+CD8- iNKT cells, constituting a median of only 1.55% iNKT cells in HIV+TB+ 
(p<0.001). In HIV-infected patients, there was a trend towards an increased percentage of 
CD4-CD8- iNKT cells (Figure 2F) and CD4-CD8+ iNKT cells (not shown), compared to 
HIV uninfected patients. To explore this further, we performed regression analysis comparing 
CD4/CD8 iNKT cell percentages in each group to HIV-TB-, adjusting for age and sex 
(Supplementary Table S2). This analysis showed evidence of reduced CD4+CD8- iNKT cells 
in HIV+TB- and HIV+TB+ compared to HIV-TB- (p<0.001 for both) and increased CD4-
CD8- percentage in HIV+TB- (p=0.010). CD4-CD8+ cells were increased in HIV+TB- 
(p=0.037) and HIV+TB+ (p=0.016) compared to HIV-TB-. For CD4/CD8 subset iNKT cell 
frequencies, see Supplementary Figure S2. 
 
iNKT cells in HIV-associated TB are pro-inflammatory with a cytotoxic phenotype 
There was high iNKT cell surface expression of the maturation marker, CD161, CD95 and 
PD1 in HIV+TB+, but not more than in the control groups (data not shown). We investigated 
iNKT cell degranulation by measuring CD107a surface expression (28). CD107a+ iNKT 
cells were increased in HIV+TB+ patients, compared to HIV+TB- patients, suggesting 
increased cytotoxic degranulation (Figure 3A), but this phenotype was not observed in all 
HIV+TB+ patients. To explore this further, we investigated association between CD107a+ 
iNKT cell positivity and TB disease phenotype in HIV+TB+. We found  significantly 
increased CD107a+ iNKT cell percentage in HIV+TB+ patients with clinical features of 
extrapulmonary TB compared to those without, consistent with the hypothesis that 
disseminated Mtb might lead to peripheral blood iNKT cell degranulation (Figure 3B).  
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In summary, we found that HIV infection was associated with iNKT cell depletion and CD4+ 
iNKT cell subsets were most significantly depleted in advanced HIV. Active TB was 
associated with a modest reduction in iNKT cell number in HIV-uninfected patients, but did 
not clearly reduce iNKT cell frequency. The immunoregulatory CD4+CD8- iNKT cell 
subset, the predominant subset in the healthy repertoire, was depleted in HIV-infected 
patients with and without active TB. CD4-CD8+ and DN iNKT cells were the dominant 
iNKT cell subsets in HIV-infected patients. There were increased CD107a+ iNKT cell 
percentages in HIV-infected patients with active TB, indicating a cytotoxic phenotype, which 
was associated with extra-pulmonary TB.  
 
iNKT cell frequency is increased in TB-IRIS patients 
Next, in a longitudinal study, we evaluated iNKT cells in patients with advanced HIV and 
recently diagnosed TB, who commenced TB treatment and then ART, and were at risk of 
paradoxical TB-IRIS. Fifty-seven participants were enrolled. Clinical features of this cohort 
have previously been reported (25). Paradoxical TB-IRIS was diagnosed in 29 (59.2%) 
patients. Participants were included if PBMC were available at least one study timepoint 
(TB0, ARV0, ARV2 and ARV4) and there was follow up to ARV12. One participant was 
excluded as no PBMC samples were available, another as they were an elite controller and 
therefore likely to be immunologically distinct, and a third due to hepatotoxicity on TB 
treatment resulting in a significant delay to ART initiation. The subsequent analysis reports 
findings from 29 TB-IRIS patients and 17 non-IRIS controls. Patient demographics and TB 
diagnosis are provided in Table 3 and were not significantly different comparing TB-IRIS 
with non-IRIS patients. Between ARV0 and ARV4, peripheral blood CD4 T cell counts 
increased (p<0.001) from median 101 cells/ l to 206 cells/ l in TB-IRIS patients and from 
99 cells/ l to 175 cells/ l in non-IRIS patients.  
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First, we enumerated iNKT cells. We found an elevated iNKT cell frequency in TB-IRIS 
compared to non-IRIS patients (Figure 4A). At ARV2, the most frequent time of TB-IRIS 
presentation, the median iNKT cell frequency per million CD3+CD19- live lymphocytes in 
TB-IRIS was 992 (IQR, 166-5682) compared to 100  (IQR 24.5-440) in non-IRIS patients 
(p=0.025 in unadjusted analysis). Multivariable modelling including data from timepoints 
ARV0, ARV2 and ARV4 demonstrated a significant association between TB-IRIS and 
increased iNKT cell frequency, adjusted for age and sex (p=0.022, Supplementary Table S3), 
but no increase in iNKT cell frequency over time and the association did not differ with total 
peripheral blood CD4 T cell count, nor HIV viral load. A similar trend was found for iNKT 
cell numbers in the adjusted logistic regression analysis (p=0.062, Supplementary Figure S3). 
 
iNKT cell function and phenotype in TB-IRIS  
Next, we examined CD4/CD8 iNKT cell subsets in the longitudinal study. CD4+ iNKT cell 
percentage and frequency were low, both in TB-IRIS and non-IRIS patients and did not 
increase in the first four weeks of ART, despite an increased peripheral blood CD4 T cell 
count. CD4+CD8- iNKT cell percentage was significantly lower in TB-IRIS patients than 
non-IRIS patients, (p=0.015 by multivariate linear regression modelling, Figure 4B and 
Supplementary Table S4). Supplementary Figure S4 shows CD4/CD8 subset frequency 
demonstrating a predominance of DN and CD4-CD8+ iNKT cells in TB-IRIS compared to 
non-IRIS patients, at ARV2 (p=0.029 and p=0.036 respectively).   
 
In both TB-IRIS and non-IRIS patients, CD161+ iNKT cell and CD107a+ iNKT cell 
percentages were dynamic (Supplementary Figure 5 A-B). CD95 cell surface expression, 
indicative of cytotoxicity,  and PD1+ iNKT cell percentages were high both in TB-IRIS and 
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non-IRIS patients whilst CD40L+ iNKT cell percentages were relatively low, possibly 
indicating iNKT cell exhaustion (Supplementary Figure S5 C-E) (22, 29). In TB-IRIS, 
CD161+ iNKT cell percentages decreased between ARV0 and ARV2, suggesting a loss of 
mature iNKT cells, whereas in non-IRIS patients, iNKT cell CD161 positivity was similar 
(Figure 5A). In TB-IRIS patients, CD107a+ iNKT cells increased between ARV0 and ARV2 
relative to non-IRIS patients, suggesting degranulation occurred at the time of IRIS symptom 
onset (Figure 5B). CD107a+ iNKT cell frequency was increased in TB-IRIS compared to 
non-IRIS patients at ARV2 (Figure 5C).  
 
In summary, patients with advanced HIV and active TB had low circulating iNKT cell 
frequency pre-ART initiation, but iNKT cell populations were skewed towards pro-
inflammatory, cytotoxic subsets. Higher iNKT cell frequency was associated with TB-IRIS 
following ART initiation and iNKT cells in TB-IRIS patients were CD4+CD8- subset 
deplete, with increased DN and CD4-CD8+ iNKT cell frequency at the time of TB-IRIS 
onset. Increased CD107a+ iNKT cell subsets in TB-IRIS patients also at ARV2 suggested 
increased iNKT cell degranulation occurring at the time of TB-IRIS presentation.  
 
Discussion 
In this study, we demonstrated low iNKT cell frequency in ART-naïve patients with 
advanced HIV infection, with a paucity of CD4+ iNKT cells, and relatively increased 
proportions of CD4-CD8- iNKT cells, representing a shift from CD4+ subsets found in HIV-
uninfected patients. Decreased iNKT cell numbers and CD4+ iNKT cell frequency were 
associated with active TB in patients without HIV infection, but this finding was not 
consistent in HIV-infected patients. In HIV-infected patients with active TB, increased 
degranulation of iNKT cells was found. Despite low iNKT cell frequencies in these patients, 
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there were relatively increased iNKT cells in patients who went on to develop TB-IRIS 
compared to those who did not and these were predominantly DN or CD4-CD8+ iNKT cells. 
There was no significant recovery in peripheral blood CD4+ iNKT cells in the first four 
weeks of ART, despite increased peripheral blood CD4 count (25).  
 
Our findings are consistent with prior human studies measuring iNKT cells in HIV infection, 
which report reduced iNKT cell frequency in HIV-infected patients (23, 30, 31). A previous 
study demonstrated that in vitro HIV-1 infection directly infects and selectively depletes 
CD4+ iNKT cells. Activated iNKT cells were more susceptible to HIV-1 infection than 
conventional CD4 T cells.  (32). In HIV-leprosy co-infection, iNKT cell populations were 
found to be reduced more profoundly than in leprosy or HIV infection alone (33). iNKT cell 
activation due to mycobacterial infection might exacerbate iNKT cell depletion in HIV-1 
infected patients. Although we found the lowest iNKT cell frequency and numbers in patients 
with HIV-1 infection and active TB, active TB did not clearly have an additive effect of 
iNKT cell depletion in HIV-infected patients. 
 
There are a number of potential mechanisms by which iNKT cells may contribute to 
immunopathology in TB-IRIS. They may directly recognise foreign or self lipid antigens 
presented via CD1d, or become activated by local cytokine networks (26). Once activated 
iNKT cells may rapidly secrete proinflammatory cytokines and chemokines promoting CD4 
T cell expansion, activation and neutrophil infiltration, features of TB-IRIS we have 
previously shown, in addition to causing cell death (5, 6, 9, 10, 26, 34). Ultimately, this 
cascade may lead to MMP activation and tissue destruction, in turn propagating 
proinflammatory cytokine secretion in the vicious cycle of hyperinflammation that is the 
hallmark of TB-IRIS (7, 25).  
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iNKT cell quantification using α-galcer-loaded CD1d-loaded tetramers, is recognised as a 
stringent method of iNKT cell quantification (35, 36). However, we cannot extrapolate our 
findings beyond the limitations of this methodology, which may be affected by TCR 
downregulation on activation, nor beyond peripheral blood into tissue compartments (35). It 
is possible that increased circulating iNKT cells in TB-IRIS patients represents failure of 
migration to tissues. We found evidence of increased iNKT cell degranulation in extra-
pulmonary TB, compared to pulmonary TB, raising the possibility that more abundant, 
disseminated Mtb antigen may drive iNKT cell degranulation in HIV-associated TB and 
increased iNKT cell cytotoxicity in TB-IRIS patients (24).   
 
As a rare T cell subset, iNKT cells have formerly been difficult to study and iNKT cell 
function in infection is a relatively understudied area. However, in the field of oncology, 
adjuvants to boost iNKT cell cytotoxicity have been the focus of translational research and 
have entered early phase clinical trials (37, 38). Our study suggests that boosting iNKT cell 
cytotoxicity would not be an appropriate strategy in HIV-associated TB. However, an 
improved understanding of the role of iNKT cells in TB immunopathology could identify 
novel therapeutic targets. As human and mouse iNKT cell physiology differ, further human 
clinical and cellular studies are required, including study of iNKT cells in tissue 
compartments.  
 
Conclusion 
This study supports a role for iNKT cells in innate immune dysfunction in paradoxical TB-
IRIS. We have shown profound CD4+ iNKT cell subset depletion in advanced HIV-1 
infection and a lesser effect of active TB in HIV-uninfected patients. In patients with 
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advanced HIV and a new diagnosis of active TB, iNKT cell populations were skewed 
towards a proinflammatory, cytotoxic phenotype. Patients who developed TB-IRIS had 
increased iNKT cells compared to non-IRIS patients and iNKT cell degranulation occurred at 
the time of IRIS, potentially contributing to immunopathology.   
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Figure Legends 
Figure 1 Reduced iNKT cells in HIV-1 infection and active TB  
iNKT cells were enumerated by flow cytometry using ⍺-galcer loaded CD1d tetramers. Each 
sample was stained in parallel with a control tetramer (without ⍺-galcer) to identify non-
specific tetramer binding for subtraction. The gating strategy shown in (A) demonstrates an 
iNKT cell frequency of 0.77%, with no control tetramer binding, equivalent to 7700 cells per 
million CD3+CD19- live lymphocytes. Decreased iNKT cell frequency (B) was found in 
HIV-infected patients with active TB (HIV+TB+) and without active TB (HIV+TB-), 
compared to HIV-uninfected patients without active TB (HIV-TB-). Similarly, in HIV-
infected patients with and without active TB, decreased iNKT cell numbers (cells per 
millilitre peripheral blood (C)) were found compared to HIV-uninfected patients without 
active TB. Additionally, in HIV-uninfected patients with active TB (HIV-TB+), iNKT cell 
numbers were reduced compared to HIV-uninfected patients without TB.  Analysis was by 
Kruskal Wallis with Dunn’s multiple comparison’s test to calculate adjusted p values: 
*p<0.05; **p<0.01; ***p<0.001. In (B) and (C), zero values were replaced by one for 
representation on a log scale. 
 
Figure 2 CD4+ iNKT cell subset depletion in HIV-1-associated TB  
HIV-infected patients, most significantly those with active TB, had depleted CD4+ iNKT 
cells as measured by percentage of total iNKT cell count (A) and frequency per million CD3+ 
CD19- live lymphocytes (B).  In HIV-infected patients, peripheral blood CD4 T cell count 
positively correlated with CD4+ iNKT cell percentage (C). HIV-1 viral load negatively 
correlated with CD4+ iNKT cell percentage (D).  In HIV-uninfected patients without active 
TB, iNKT cells were mostly either CD4+ CD8- or double negative (CD4-CD8-), whilst in 
HIV-infected patients CD4+ CD8- iNKT cells were depleted and double negative iNKT cells 
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were the predominant subset (E, F). Analysis was by Kruskal Wallis with Dunn’s multiple 
comparisons test to calculate multiplicity-adjusted p values: * p<0.05; ** p<0.01; *** 
p<0.001 or by Spearman’s correlation (C, D). 
 
Figure 3 iNKT cell cytotoxicity in HIV-associated TB  
In HIV-associated TB, there were increased percentages of CD107a+ iNKT cells, suggestive 
of cytotoxic degranulation (A). In HIV-infected patients with clinical features of extra-
pulmonary TB (EPTB), there were increased CD107a+ iNKT cell percentages compared to 
HIV-infected patients with pulmonary TB (B). Analysis was by Kruskal Wallis with Dunn’s 
multiple comparisons test to calculate multiplicity-adjusted p values or by Mann-Whitney U 
in (D): * p<0.05.  
 
Figure 4 iNKT cells are elevated in TB-IRIS patients and are CD4+CD8- subset 
deplete 
iNKT cells were enumerated longitudinally by flow cytometry using ⍺-galcer loaded CD1d 
tetramers, in a cohort of 46 HIV-1-infected patients with active TB. Samples were collected 
around the time of TB diagnosis (TB0), at anti-retroviral therapy initiation (ARV0, a median 
of 17.5 days post TB treatment initiation) and at two weeks (ARV2) and four weeks (ARV4) 
post-ART initiation although not all patients contributed data to the first timepoint as patients 
who had taken more than four doses of TB treatment at  enrolment contributed data from 
ARV0, resulting in fewer data points at TB0. TB-IRIS presentation was typically at ARV2. 
Increased iNKT cell frequency (A) was observed in TB-IRIS patients compared to non-IRIS 
controls. CD4+CD8- iNKT cell percentages were reduced in TB-IRIS patients (B). Statistical 
analysis was by multivariable negative binomial modelling to examine associations of iNKT 
cell frequency and number with TB-IRIS status and by multivariate linear regression 
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modelling to estimate difference in CD4/CD8 cell subset percentages between TB IRIS and 
non-IRIS patients, including data from all timepoints to derive p values which are reported on 
the corresponding figure. In (A), zero values were replaced by one for representation on a log 
scale.  
 
Figure 5 iNKT cell cytotoxicity associated with TB-IRIS  
iNKT cells were characterised longitudinally by flow cytometric analysis for surface markers 
CD161 and CD107a, in TB-IRIS patients and non-IRIS patients . Between ARV0 and ARV2, 
CD161+ iNKT cells there was a reduction in CD161+ iNKT cell percentage in TB-IRIS 
compared to non-IRIS patients (A), whereas CD107a+ iNKT cell percentage increased in TB-
IRIS patients between ARV0 and ARV2, compared to non-IRIS patients (B). CD107a+ iNKT 
cell frequency (cells per million CD3+CD19- live lymphocytes) was increased in TB-IRIS 
patients compared to non-IRIS controls at ARV2, the most common time of TB-IRIS 
presentation (C). Mann-Whitney U analysis for TB-IRIS vs non-IRIS: * p<0.05; **p<0.01. 
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Table 1 Demographic and clinical features of the cross-sectional study participants 
 
  HIV-TB- HIV-TB+ HIV+TB- HIV+TB+ p value 
 
n 
32 20 26 23   
Female, n (%) 14 (43.8) 7 (35.0) 15 (57.7) 9 (39.1) >0.100a 
Smoking status: 
 current or ex,, n (%) 
17 (53.1) 10 (50.0) 9 (34.6) 9 (39.1) >0.100a 
Age, median years (IQR) 29.0 (23.3-38.8) 38.0 (30.0-42.8) 32.5 (28.5-35.3) 31.0 (28.0-40.0) 0.059b 
CD4 T cell count,  
median cells/ml (IQR) 
N/A N/A 349 (204-483) 187 (104-386) 0.041 
CD4 T cell percentage, 
median (IQR) 
N/A N/A 17.8 (12.0-22.3) 13.7 (9.22-26.3) 0.901 
HIV viral load,  
median copies/ml (IQR) 
N/A N/A 25735 (6807-
92169) 
296196 (13540-
503097) 
0.031 
      
Symptomatic, n (%) 16 (50.0) 20 (100) 10 (38.5) 23 (100)  
Duration of symptoms, median 
days (IQR) 
14.0 (4.00-150) 28.0 (14.0-30.0) 60.0 (11.3-82.5) 30.0 (21.0-30.5) 0.595C 
Miliary TB, n (%) 0 (0) 0 (0) 0 (0) 5 (21.7) 0.051d 
Extrapulmonary TB, n (%) N/A 3 (15.0) N/A 10 (43.5) 0.054d 
Smear positive TB, n (%) 0 (0) 13 (65.0) 0 (0) 8 (34.8) 0.069d 
Culture positive TB, n (%) 0 (0) 10 (50.0) (0) 18 (78.3) 0.064d 
Clinical diagnosis TB, n (%) 0 (0) 3 (15.0) 0 (0) 2 (8.70) 0.650 
Cavitary disease on CXR,  
n (%) 
0 (0) 14 (70.0) 0 (0) 9 (39.1) 0.067d 
 
afor comparison between each group by Fisher’s Exact test 
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bfor comparison of all groups by Kruskal-Wallis test, Dunn’s multiple comparisons test for a difference between HIV-TB- and HIV-
TB+ (p=0.033) 
cfor comparison of all groups by Kruskal-Wallis test 
dfor comparison between HIV-TB+ and HIV+TB+ by Fisher’s Exact test 
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Table 2 iNKT cell enumeration in cross-sectional study participants by diagnosis 
 
Patient category Dunn’s multiple comparisons test 
HIV- TB- HIV- TB+ HIV+TB- HIV+TB+ HIV- TB- vs. 
HIV- TB+ 
HIV- TB- vs. 
HIV+TB- 
HIV- TB- vs. 
HIV+TB+ 
HIV+TB- vs. 
HIV+TB+ 
HIV- TB+ vs. 
HIV+TB+ 
 
iNKT cell frequency, median per million CD3+CD19- live lymphocytes (IQR) 
 
1700  
(1125, 2600) 
735  
(253, 1800) 
375  
(198, 1775) 
280  
(62.7, 
1300) 
0.149 0.005 0.001 >0.999 0.731 
 
iNKT cell number, median cells per ml blood (IQR) 
 
 
282628 
(151100, 
487870) 
88580 
(29600, 
203771) 
44965 
(19635, 
219669) 
24439 
(3789, 
119449) 
0.044 0.002 <0.001 0.432 0.161 
 
CD4+ iNKT cells, median percentage (IQR) 
 
 
44.5  
(27.9, 61.1) 
38.9  
(16.3, 67.1) 
13.67 
(2.77, 39.2) 
3.15  
(0, 39.6) 
>0.999 0.005 <0.001 >0.999 0.007 
 
CD4+ iNKT cell frequency, median per million CD3+ CD19- live lymphocytes (IQR) 
 
 
712  
(451, 1043) 
202  
(78.8, 601) 
100  
(11.5, 236) 
18.9  
(0, 148) 
0.016 <0.001 <0.001 >0.999 0.013 
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Table 3 Demographic and clinical features of participants in longitudinal study at enrolment 
 
 TB-IRIS non-IRIS p value 
n (%) 29 (63.0) 17 (37.0)  
Female, n (%) 14 (48.3) 10 (58.8) 0.552 
Smoking status: current or ex-, n (%) 9 (31.0) 3 (17.5) 0.489 
Age, median years (IQR) 35.0 (29.5-42.0) 35.0 (30.5-43.0) 0.924 
CD4 T cell count, median cells/ l 
 (IQR) 
89.0  
(64.0-141.5) 
82.0  
(69.5-145.5) 
0.987 
HIV-1 viral load, median copies/ml  
(IQR) 
621075  
(207018-1185455) 
520295  
(126925-1029554) 
0.343 
Extrapulmonary TB, n (%) 21 (72.4) 12 (70.6) 1.00 
Miliary TB, n (%) 5 (17.2) 1 (5.88) 0.390 
Smear positive TB, n (%) 14 (48.3) 5 (29.4) 0.235 
Culture positive TB, n (%) 21 (72.4) 11 (64.7) 0.742 
Clinical diagnosis TB, n (%) 2 (6.90) 4 (23.5) 0.174 
ART initiation, days post TB treatment initiation 
(IQR) 
15  
(14-28) 
21  
(14-41) 
0.186 
IRIS symptom onset, median days post-ART 
initiation (IQR) 
6  
(4-10) 
N/A  
IRIS presentation, median days post-ART initiation 
(IQR) 
14  
(9-15) 
N/A  
INSHIa criteria for paradoxical TB-IRIS  fulfilled, n 
(%) 
25 (86.2) 0 (0)  
 
aInternational Network for the Study of HIV-associated IRIS 
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Figure 1 
 
 
  
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciz501/5514487 by St G
eorge's U
niversity of London user on 24 June 2019
  30 
Figure 2 
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Figure 3 
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Figure 4 
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Figure 5 
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